Investigation of toxic metabolites during drug development

Toxicology and Applied Pharmacology

Volumn 207, Issue 2 SUPPL., 2005, Pages 425-434

  Park, Kevin ^a   Williams, Dominic P ^a   Naisbitt, Dean J ^a   Kitteringham, Neil R ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Bioactivation; Bioinactivation; Critical protein antigen; Drug metabolism

Indexed keywords

ANALGESIC AGENT; ANTIINFECTIVE AGENT; BROMOBENZENE; CARBON TETRACHLORIDE; FUROSEMIDE; PARACETAMOL; SULFAMETHOXAZOLE; SULFONAMIDE; TOXIN;

BIOCHEMISTRY; CELL DAMAGE; CHEMICAL CARCINOGENESIS; CLINICAL CHEMISTRY; CONFERENCE PAPER; COVALENT BOND; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG STABILITY; DRUG WITHDRAWAL; EXPERIMENTAL ANIMAL; GENETIC ENGINEERING; HUMAN; LIVER CELL; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; MOLECULAR DYNAMICS; MOLECULAR GENETICS; NONHUMAN; PHARMACOPHORE; PROTEIN EXPRESSION; SOMATIC CELL GENETICS; T LYMPHOCYTE ACTIVATION; TISSUE INJURY;

ANIMALIA;

EID: 24644440657     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2005.02.029     Document Type: Conference Paper

References (65)

1. B.S. Andersson, M. Rundgren, S.D. Nelson, and S. Harder N-acetyl-p-benzoquinone imine-induced changes in the energy metabolism in hepatocytes Chem. Biol. Interact. 75 1990 201 211
2. M.E. Blazka, M.R. Elwell, S.D. Holladay, R.E. Wilson, and M.I. Luster Histopathology of acetaminophen-induced liver changes-Role of interleukin-1-alpha and tumor-necrosis-factor-alpha Toxicol. Pathol. 24 1996 181 189
3. B.B. Brodie, W.D. Reid, A.K. Cho, G. Sipes, G. Krishna, and J.R. Gillette Possible mechanism of liver necrosis caused by aromatic organic compounds Proc. Natl. Acad. Sci. U.S.A. 68 1971 160 164
4. S.J. Bulera, S.M. Eddy, E. Ferguson, T.A. Jatkoe, J.F. Reindel, M.R. Bleavins, and F.A. De La Iglesia RNA expression in the early characterization of hepatotoxicants in Wistar rats by high-density DNA microarrays Hepatology 33 2001 1239 1258
5. P.C. Burcham, and A.W. Harman Acetaminophen toxicity results in site-specific mitochondrial damage in isolated mouse hepatocytes J. Biol. Chem. 266 1991 5049 5054
6. C. Burkhart, S. von Greyerz, J.P. Depta, D.J. Naisbitt, M. Britschgi, K.B. Park, and W.J. Pichler Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole- metabolite-specific human CD4+ T-cells Br. J. Pharmacol. 132 2001 623 630
7. C. Burkhart, M. Britschgi, I. Strasser, J.P. Depta, S. von Greyerz, V. Barnaba, and W.J. Pichler Non-covalent presentation of sulfamethoxazole to human CD4+ T cells is independent of distinct human leukocyte antigen-bound peptides Clin. Exp. Allergy 32 2002 1635 1643
8. J.T. Buters, S. Sakai, T. Richter, T. Pineau, D.L. Alexander, U. Savas, J. Doehmer, J.M. Ward, C.R. Jefcoate, and F.J. Gonzalez Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas Proc. Natl. Acad. Sci. U.S.A. 96 1999 1977 1982
9. A.A. Constan, C.S. Sprankle, J.M. Peters, G.L. Kedderis, J.I. Everitt, B.A. Wong, F.L. Gonzalez, and B.E. Butterworth Metabolism of chloroform by cytochrome P450 2E1 is required for induction of toxicity in the liver, kidney, and nose of male mice Toxicol. Appl. Pharmacol. 160 1999 120 126
10. A.E. Cribb, and S.P. Spielberg Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine Drug Metab. Dispos. 18 1990 784 787
11. D.C. Davis, W.Z. Potter, D.J. Jollow, and J.R. Mitchell Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen Life Sci. 14 1974 2099 2109
12. O.B. Engler, I. Strasser, D.J. Naisbitt, A. Cerny, and W.J. Pichler A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals Toxicology 197 2004 47 56
13. J. Farrell, D.J. Naisbitt, N.S. Drummond, J.P. Depta, F.J. Vilar, M. Pirmohamed, and B.K. Park Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans J. Pharmacol. Exp. Ther. 306 2003 229 237
14. S. Gallucci, and P. Matzinger Danger signals: SOS to the immune system Curr. Opin. Immunol. 13 2001 114 119
15. H.J. Gill, J.L. Maggs, S. Madden, M. Pirmohamed, and B.K. Park The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole Br. J. Clin. Pharmacol. 42 1996 347 353
16. H.J. Gill, S.J. Hough, D.J. Naisbitt, J.L. Maggs, N.R. Kitteringham, M. Pirmohamed, and B.K. Park The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat J. Pharmacol. Exp. Ther. 282 1997 795 801
17. J.R. Gillette, J.R. Mitchell, and B.B. Brodie Biochemical mechanisms of drug toxicity Annu. Rev. Pharmacol. 14 1974 271 288
18. R.D. Goldin, I.D. Ratnayaka, C.S. Breach, I.N. Brown, and S.N. Wickramasinghe Role of macrophages in acetaminophen (paracetamol)-induced hepatotoxicity J. Pathol. 179 1996 432 435
19. C.E. Goldring, N.R. Kitteringham, R. Elsby, L.E. Randle, Y.N. Clement, D.P. Williams, M. McMahon, J.D. Hayes, K. Itoh, M. Yamamoto, and B.K. Park Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice Hepatology 39 2004 1267 1276
20. F.J. Gonzalez Transgenic models in xenobiotic metabolism and toxicology Toxicology 181-182 2002 237 239
21. F.J. Gonzalez Role of gene knockout and transgenic mice in the study of xenobiotic metabolism Drug Metab. Rev. 35 2003 319 335
22. D.J. Irvine, M.A. Purbhoo, M. Krogsgaard, and M.M. Davis Direct observation of ligand recognition by T cells Nature 419 2002 845 849
23. M. Karbowski, C. Kurono, M. Wozniak, M. Ostrowski, M. Teranishi, Y. Nishizawa, J. Usukura, T. Soji, and T. Wakabayashi Free radical-induced megamitochondria formation and apoptosis Free Radical Biol. Med. 26 1999 396 409
24. N.R. Kitteringham, H. Powell, C.J. Henderson, C.R. Wolf, and B.K. Park Protection against paracetamol hepatotoxicity in glutathione S-transferase pi knockout mice does not involve altered covalent binding Br. J. Clin. Pharmacol. 48 1999 887P 888P
25. N.R. Kitteringham, H. Powell, Y.N. Clement, C.C. Dodd, J.N. Tettey, M. Pirmohamed, D.A. Smith, L.I. McLellan, and B.K. Park Hepatocellular response to chemical stress in CD-1 mice: induction of early genes and gamma- glutamylcysteine synthetase Hepatology 32 2000 321 333
26. D.L. Laskin, and A.M. Pilaro Potential role of activated macrophages in acetaminophen hepatotoxicity: I. Isolation and characterization of activated macrophages from rat liver Toxicol. Appl. Pharmacol. 86 1986 204 215
27. D.L. Laskin, A.M. Pilaro, and S. Ji Potential role of activated macrophages in acetaminophen hepatotoxicity: II. Mechanism of macrophage accumulation and activation Toxicol. Appl. Pharmacol. 86 1986 216 226
28. W.M. Lee Drug-induced hepatotoxicity N. Engl. J. Med. 349 2003 474 485
29. S.S. Lee, J.T. Buters, T. Pineau, P. Fernandez-Salguero, and F.J. Gonzalez Role of CYP2E1 in the hepatotoxicity of acetaminophen J. Biol. Chem. 271 1996 12063 12067
30. J. Liu, L.E. Sendelbach, A. Parkinson, and C.D. Klaassen Endotoxin pretreatment protects against the hepatotoxicity of acetaminophen and carbon tetrachloride: role of cytochrome P450 suppression Toxicology 147 2000 167 176
31. P. Matzinger Tolerance, danger, and the extended family Annu. Rev. Immunol. 12 1994 991 1045
32. E. Miller, and J. Miller The presence and significance of bound aminoazo dyes in the livers of rats fed p-dimethylaminobenzene Cancer Res. 7 1947 468 480
33. E. Miller, and J. Miller In vivo combinations between carcinogens and tissue constituents and their possible role in carcinogenesis Cancer Res. 12 1952 547 556
34. D.J. Naisbitt, P.M. O'Neill, M. Pirmohamed, and B.K. Park Synthesis and reactions of nitroso sulphamethoxazole with biological nucleophiles: implications for immune mediated toxicity Bioorg. Med. Chem. Lett. 6 1996 1511 1516
35. D.J. Naisbitt, S.J. Hough, H.J. Gill, M. Pirmohamed, N.R. Kitteringham, and B.K. Park Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity Br. J. Pharmacol. 126 1999 1393 1407
36. D. Naisbitt, S. Gordon, M. Pirmohamed, and B. Park Immunological principles of adverse drug reactions. The initiation and propagation of immune responses elicited by drug treatment Drug Saf. 23 2000 483 507
37. D.J. Naisbitt, S.F. Gordon, M. Pirmohamed, C. Burkhart, A.E. Cribb, W.J. Pichler, and B.K. Park Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo Br. J. Pharmacol. 133 2001 295 305
38. D.J. Naisbitt, J. Farrell, S.F. Gordon, J.L. Maggs, C. Burkhart, W.J. Pichler, M. Pirmohamed, and B.K. Park Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation Mol. Pharmacol. 62 2002 628 637
39. B.K. Park, and N.R. Kitteringham Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications Drug Metab. Rev. 26 1994 605 643
40. B.K. Park, and J.L. Maggs Inter-individual variation in the metabolism of ethynylestradiol Prog. Clin. Biol. Res. 214 1986 289 302
41. B.K. Park, and M. Pirmohamed Toxicogenetics in drug development Toxicol. Lett. 120 2001 281 291
42. B.K. Park, M. Pirmohamed, and N.R. Kitteringham Idiosyncratic drug reactions: a mechanistic evaluation of risk factors Br. J. Clin. Pharmacol. 34 1992 377 395
43. B.K. Park, M. Pirmohamed, and N.R. Kitteringham Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective Chem. Res. Toxicol. 11 1998 969 988
44. W.D. Pennie, N.J. Woodyatt, T.C. Aldridge, and G. Orphanides Application of genomics to the definition of the molecular basis for toxicity Toxicol. Lett. 120 2001 353 358
45. M. Pirmohamed, and D.J. Back The pharmacogenomics of HIV therapy Pharmacogenomics J. 1 2001 243 253
46. M. Pirmohamed, and B.K. Park Genetic susceptibility to adverse drug reactions Trends Pharmacol. Sci. 22 2001 298 305
47. M. Pirmohamed, and B.K. Park HIV and drug allergy Curr. Opin. Allergy. Clin. Immunol. 1 2001 311 316
48. M. Pirmohamed, S. James, S. Meakin, C. Green, A.K. Scott, T.J. Walley, K. Farrar, B.K. Park, and A.M. Breckenridge Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients BMJ 329 2004 15 19
49. J.L. Raucy, J.M. Lasker, C.S. Lieber, and M. Black Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2 Arch. Biochem. Biophys. 271 1989 270 283
50. T.P. Reilly, L.H. Lash, M.A. Doll, D.W. Hein, P.M. Woster, and C.K. Svensson A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions J. Invest. Dermatol. 114 2000 1164 1173
51. T.P. Reilly, M. Bourdi, J.N. Brady, C.A. Pise-Masison, M.F. Radonovich, J.W. George, and L.R. Pohl Expression profiling of acetaminophen liver toxicity in mice using microarray technology Biochem. Biophys. Res. Commun. 282 2001 321 328
52. B. Schnyder, D. Mauri-Hellweg, M. Zanni, F. Bettens, and W.J. Pichler Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones J. Clin. Invest. 100 1997 136 141
53. B. Schnyder, C. Burkhart, K. Schnyder-Frutig, S. von Greyerz, D.J. Naisbitt, M. Pirmohamed, B.K. Park, and W.J. Pichler Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals J. Immunol. 164 2000 6647 6654
54. Y. Shi, W. Zheng, and K.L. Rock Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses Proc. Natl. Acad. Sci. U.S.A. 97 2000 14590 14595
55. K.E. Thummel, C.A. Lee, K.L. Kunze, S.D. Nelson, and J.T. Slattery Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4 Biochem. Pharmacol. 45 1993 1563 1569
56. J.L. Valentine, S.S. Lee, M.J. Seaton, B. Asgharian, G. Farris, J.C. Corton, F.J. Gonzalez, and M.A. Medinsky Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression Toxicol. Appl. Pharmacol. 141 1996 205 213
57. R.E. Vance Cutting edge: cutting edge commentary: a Copernican revolution? Doubts about the danger theory J. Immunol. 165 2000 1725 1728
58. H. Wang, B. Chanas, and B.I. Ghanayem Cytochrome P450 2E1 (CYP2E1) is essential for acrylonitrile metabolism to cyanide: comparative studies using CYP2E1-null and wild-type mice Drug Metab. Dispos. 30 2002 911 917
59. J.F. Waring, R.A. Jolly, R. Ciurlionis, P.Y. Lum, J.T. Praestgaard, D.C. Morfitt, B. Buratto, C. Roberts, E. Schadt, and R.G. Ulrich Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles Toxicol. Appl. Pharmacol. 175 2001 28 42
60. D.P. Williams, and D.J. Naisbitt Toxicophores: groups and metabolic routes associated with increased safety risk Curr. Opin. Drug Discovery Dev. 5 2002 104 115
61. D.P. Williams, and B.K. Park Idiosyncratic toxicity: the role of toxicophores and bioactivation Drug Discovery Today 8 2003 1044 1050
62. D.P. Williams, N.R. Kitteringham, D.J. Naisbitt, M. Pirmohamed, D.A. Smith, and B.K. Park Are chemically reactive metabolites responsible for adverse reactions to drugs? Curr. Drug Metab. 3 2002 351 366
63. D.P. Williams, C. Garcia-Allan, G. Hanton, J.L. Lenet, J.P. Provost, P. Brain, R. Walsh, G.I. Johnston, D.A. Smith, and B.K. Park Time course toxicogenomic profiles in CD-1 mice after nontoxic and nonlethal hepatotoxic paracetamol administration Chem. Res. Toxicol. 17 2004 1551 1561
64. H. Zaher, J.T. Buters, J.M. Ward, M.K. Bruno, A.M. Lucas, S.T. Stern, S.D. Cohen, and F.J. Gonzalez Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice Toxicol. Appl. Pharmacol. 152 1998 193 199
65. H. Zhang, J. Cook, J. Nickel, R. Yu, K. Stecker, K. Myers, and N.M. Dean Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis Nat. Biotechnol. 18 2000 862 867